• <legend id="ssac2"><optgroup id="ssac2"></optgroup></legend>
    <menu id="ssac2"></menu>
  • PRINT OUT

    Product Pipeline

    May 14, 2021

    <Domestic>

    Stage Code No.
    (Generic name)
    Therapeutic field Indications Origin Development
    Launch
    Phase III
    NS-065/NCNP-01
    (viltolarsen)
    intractable disease?orphan disease Duchenne muscular dystrophy Co - development:
    National Center of Neurology and Psychiatry
    Nippon Shinyaku
    NDA filing NS-304
    (selexipag)
    intractable disease?orphan disease chronic thromboembolic pulmonary
    hypertension
    Nippon Shinyaku Co - development:
    Janssen Pharmaceutical K.K.
    NDA filing NS-32
    (ferric derisomaltose)
    gynecology iron deficiency anemia Licensed - in from
    Pharmacosmos A/S
    Nippon Shinyaku
    Phase III ZX008 intractable disease?orphan disease Dravet syndrome
    Lennox-Gastaut syndrome
    Licensed - in from
    Zogenix, Inc.
    Zogenix, Inc.
    Phase II NS-304
    (selexipag)
    cardiovascular arteriosclerosis obliterans Nippon Shinyaku Nippon Shinyaku
    Phase II NS-304
    (selexipag)
    orthopedics lumbar spinal stenosis Nippon Shinyaku Nippon Shinyaku
    Phase II NS-304
    (selexipag)
    cardiovascular pediatric pulmonary arterial hypertension Nippon Shinyaku Co - development:
    Janssen Pharmaceutical K.K.
    Phase II NS-580 gynecology endometriosis Nippon Shinyaku Nippon Shinyaku
    Phase I/II NS-87 hematologic malignancies secondary acute myeloid leukemia Licensed - in from
    Jazz Pharmaceuticals plc
    Nippon Shinyaku
    Phase I NS-229 inflammatory diseases inflammatory diseases Nippon Shinyaku Nippon Shinyaku
    Preparation for Phase I NS-917 hematologic malignancies relapsed/refractory acute myeloid leukemia Licensed - in from
    Delta-Fly Pharma, Inc.
    Nippon Shinyaku
    Preparation for development NS-401
    (tagraxofusp)
    hematologic malignancies blastic plasmacytoid dendritic cell neoplasm Licensed - in from
    The Menarini Group
    Nippon Shinyaku

    <Overseas>

    Stage Code No.
    (Generic name)
    Therapeutic field Indications Origin Development
    US Launch
    Phase III
    NS-065/NCNP-01
    (viltolarsen)
    intractable disease?orphan disease Duchenne muscular dystrophy Co - development:
    National Center of Neurology and Psychiatry
    Nippon Shinyaku
    Phase III NS-304
    (selexipag)
    intractable disease?orphan disease chronic thromboembolic pulmonary
    hypertension
    Nippon Shinyaku Licensed - out to
    Johnson & Johnson
    Preparation for Phase II NS-018
    (ilginatinib)
    hematologic malignancies myelofibrosis Nippon Shinyaku Nippon Shinyaku
    page-top
    99re8热视频这在线视频_日本一区二区三区日本免费_男女边摸边做激情视频_和老外3p爽粗大免费视频